• Innovation and Value Initiative
    IVI is finding common ground in approaches to measuring value in healthcare.
    LEARN MORE
  • We aim to drive waste out of the system.
    Rising costs can be mitigated while preserving incentives to develop future generations of medical breakthroughs.
    LEARN MORE
  • The value of value assessment
    We agree, costs should reflect value.
    Now let’s explore how value is measured.
    LEARN MORE
  • What is the value of a priceless cure?
    A hypothetical case in point.
    LEARN MORE
Research Innovation and Value Initiative research and policy proposals are developed by renowned thought leaders and respected researchers with the goal of leveraging evidence to improve the US healthcare system VIEW ALL

Value measurement

Develop state-of-the-art methods for measuring the value of new medical technologies. Educate and advise practitioners, healthcare system stakeholders, and policy makers about these methods to ensure they become a part of standard practice.

LEARN MORE

Innovative pricing

Develop, test, and evaluate new strategies for linking prices to value. Ensure that prices reflect value to both patients and the broader healthcare system, and that patients receive effective care.

LEARN MORE

Technology assessment

Provide scientifically credible, objective, and timely review of emerging technologies using advanced methods, representing multiple perspectives, to identify key areas of uncertainty and opportunities for value-based pricing.

LEARN MORE

Policy analysis

Conduct and disseminate research to educate the public and policy makers about the value of medical innovation, and policy reforms that can better ensure value-based pricing in US healthcare markets.

LEARN MORE
Publications Our Findings and Perspectives Building the case for broader conceptions of value and solutions to the problem of encouraging high-value care.

JAMA 2016

Utility of Cancer Value Frameworks for Patients, Payers, and Physicians

This viewpoint, authored by Dr. Chandra, Dr. Shafrin, and Dr. Dhawan, describes the differences between various cancer value frameworks and provides recommendations for improving them for clinicians, patients, and payers. In recent years, novel cancer therapies have improved the expected survival of patients but have also increased treatment costs. 

READ MORE

Health Affairs Blog 2016

Discovering New Medicines And New Ways To Pay For Them

While the rest of the health care system is moving toward paying for value, payments for drugs largely continue to be stuck in a 20th century construct that focuses on price, regardless of the health outcomes of each patient. This lack of payment innovation is particularly damaging in an era where on the horizon new treatments and cures promise great benefit for consumers, but also bring great upfront costs for individuals, employers, and governments at every level. This article proposes a new path forward.

READ MORE

Harvard Business Review 2015

Understanding Health Care's Short-Termism Problem

The meaning of "value" varies by each stakeholder and is thereore the least well understood. Drs. Chandra and Goldman discuss that the right way to think about value in health care delivery is a stream of benefiƒts accrued over a lifetime that is attractive relative to the price paid to acquire them. Using examples with schizophrenia, hepatitis c, and kidney cancer, a value-based design would avoid a "one-size-fits-all" view of drug coverage. Regardless, the challenge is to fiƒgure out how to create and develop policies to reward long-term benefits.

READ MORE

Research Synthesis Methods 2012

Accounting for correlation in network meta-analysis with multi-arm trials

Multi-arm trials are particularly valuable forms of evidence for network meta-analysis (NMA). Trial results are available either as arm-level summaries, where effect measures are reported for each arm or as contrast-level summaries, where the differences in effect between arms compare with the control arm chosen for the trial.

READ MORE
Leadership Leaders in Research and Value Assessment IVI leverages unmatched scientific expertise to answer the big questions in health care

Samuel Nussbaum

Chair of the Panel of Health Advisors

VIEW BIO

Dr. Nussbaum is currently a Senior Fellow at the Schaeffer Center for Health Policy and Economics at the University of Southern California. Prior to that, Dr. Nussbaum was the executive vice president and chief medical officer of Anthem. During a 15-year tenure, he oversaw medical and pharmacy policy, health improvement, care management, provider contracting, innovative payment models, and outcomes research and drug safety through HealthCore, an Anthem subsidiary. Dr. Nussbaum had a 20-year career as a professor at Harvard Medical School and led a basic and clinical research program at Massachusetts General Hospital where he directed the endocrine group practice. Dr. Nussbaum serves on the boards of the National Quality Forum, the OASIS Institute, and BioCrossroads and previously served as President of the Disease Management Association of America, Chairman of the National Committee for Quality Health Care, Chair of America’s Health Insurance Plan’s Chief Medical Officer Leadership Council, and on the Secretary of Health and Human Services Advisory Committee on Genetics, Health, and Society. Dr. Nussbaum has twice been recognized by Modern Healthcare as one of the “50 Most Influential Physician Executives in Healthcare.”

Darius Lakdawalla

Executive Director

VIEW BIO

Dr. Lakdawalla is the Chief Scientific Officer at Precision Health Economics and the Quintiles Chair in Pharmaceutical and Regulatory Innovation at the University of Southern California School of Pharmacy and Price School of Public Policy. He is the winner of numerous awards in health economics, including the Garfield Prize and the Milken Institute Distinguished Research Award. Dr. Lakdawalla is also a Research Associate at the National Bureau of Economic Research, Visiting Scholar at the American Enterprise Institute, and Associate Editor at the Review of Economics and Statistics and the American Journal of Health Economics, and an Editorial Board member at the Journal of Health Economics.

Jason Shafrin

Director of Research

VIEW BIO

Dr. Shafrin is a Senior Research Economist and the Director of Healthcare Quality and Value-Based Research Methods at Precision Health Economics. He is an expert in value-based purchasing, Medicare reimbursement systems, and advanced econometric analyses using claims data. Dr. Shafrin has extensive experience in estimating the value of new technologies—including traditional and digital medicines—across a variety of disease areas. For instance, Dr. Shafrin has conducted several analyses comparing patient and provider valuations of innovative treatments. He is an expert in the evolving field of value frameworks.

Carolyn Hillegass

Director of Development

VIEW BIO

Ms. Hillegass is Vice President, Business Development for Precision Health Economics, working closely with clients and key stakeholders on each research engagement. She harnesses over 25 years of global sales and marketing experience and strong knowledge across therapeutic areas, policy and public health issues. Ms. Hillegass has held senior level positions within medical imaging, pharmaceutical and life sciences organizations. She was instrumental in growing the Optum Life Sciences businesses, launching new medicines for Sanofi, and introducing FujiFilm’s digital imaging systems to the U.S. hospital market.

Mark Linthicum

Director of Scientific Communications

VIEW BIO

Mr. Linthicum is a Senior Research Scientist and Director of Scientific Communications at Precision Health Economics. At PHE, Mr. Linthicum leads the coordination of multiple research portfolios and specializes in translating scientific content for multiple audiences. Mr. Linthicum has over 10 years of experience in health policy and public health, with experience in policy-facing research in diverse therapeutic areas, including oncology, hepatology, infectious disease, and nutrition.

Suepattra May-Slater

Associate Director of Patient Engagement

VIEW BIO

Suepattra May-Slater is a Senior Research Anthropologist at Precision Health Economics and has expertise in medical anthropology and qualitative research methods. At PHE, Dr. May-Slater’s work incorporates a spectrum of qualitative research methods across diverse therapeutic areas. Her work includes designing focus groups and developing surveys to investigate both physician and patient preferences for treatment as well as designing and conducting in-depth interviews with key opinion leaders on the impact of healthcare legislation and policy on healthcare delivery and patient outcomes. Prior to her work at PHE, Dr. May-Slater served as an Assistant Research Anthropologist at the Palo Alto Medical Foundation Research Institute. In this role, Dr. May-Slater led studies on patient engagement, treatment decision-making, and patient-centered outcomes research.

 

X
Close
X
Close